TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Zoledronic Acid and Positron Emission Tomography in Treating Patients With Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed non-small cell lung cancer~  * Stage IIIB (with pleural effusion) or stage IV disease~* Candidate for systemic therapy~* Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan~* No active brain metastases~  * More than 7 days since prior radiotherapy for brain metastases~ * Must be neurologically stable with no seizures within the past 3 weeks~PATIENT CHARACTERISTICS:~* ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%~* WBC ≥ 3,000/mm³~* ANC ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* AST or ALT ≤ 2.5 times ULN (5 times ULN if liver metastases present)~* Creatinine normal OR creatinine clearance ≥ 60 mL/min by Cockcroft-Gault formula~* No current active dental problems, including infection of the teeth or jawbone (maxilla or mandible)~* No dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw, of exposed bone in the mouth, or of slow healing after dental procedures~* Not pregnant~* No uncontrolled intercurrent illness including, but not limited to, any of the following:~  * Ongoing or active infection~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia~ * Psychiatric illness/social situations that would limit compliance with study requirements~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior or other concurrent bisphosphonates~* More than 2 weeks since prior surgery~* More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered~* More than 7 days since prior palliative radiotherapy and recovered~* More than 6 weeks since prior and no planned dental or jaw surgery~* More than 30 days since prior participation in an investigational trial~* No other concurrent investigational agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3'-deoxy-3'-[18F]FLT PET & zoledronic acid (Type: EXPERIMENTAL): Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid~Single photon emission computed tomography. Patient should receive the dose of zoledronic acid within 48 hrs of the first '3'-deoxy-3'-\[18F\]FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tapering Off Antidepressants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Currently taking an FDA-approved antidepressant for at least four weeks on the list of approved medications: SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, vilazodone or vortioxetine), SNRIs (desvenlafaxine, duloxetine, levomilnacipran, venlafaxine) and other classes (amitriptyline, bupropion, desipramine, doxepin, mirtazapine, nefazodone, nortriptyline, phenelzine, selegiline, or tranylcypromine). Clomipramine, a tricyclic antidepressant approved for the treatment of OCD, will also be included, but will be classed as an SSRI for this study because inhibition of the serotonin transporter is its primary therapeutic mechanism.~* No longer wish to take the antidepressant medication they are currently prescribed, due to one of the following reasons: 1) ineffective for symptoms; 2) intolerable side effect; 3) improvement of their illness for sufficient duration that it is clinically appropriate to consider tapering the medication.~* Primary psychiatric diagnosis of major depressive disorder, an anxiety disorder, OCD, or PTSD.~* Ability to read and understand English language.~Exclusion Criteria:~* Has met criteria at any time during their life for a primary psychotic disorder (e.g. schizophrenia), or dementia.~* Meets criteria for DSM-5-defined substance use disorder within three months of the screening visit.~* Currently taking two or more antidepressants.~* Presents with a clinically significant suicide risk, as assessed by a study physician.~* Presence of any unstable or central nervous system-related medical illness that would interfere with cognition or participation.~* Women who are currently pregnant or lactating, or plan to become pregnant during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Taper A Regimen (Type: ACTIVE_COMPARATOR): Participants taking an antidepressant for at least four weeks and no longer wish to take the antidepressant medication will undergo a Two-Week Taper Regimen to discontinue their medication.
- Taper B Regimen (Type: ACTIVE_COMPARATOR): Participants taking an antidepressant for at least four weeks and no longer wish to take the antidepressant medication will undergo a One-Week Taper Regimen to discontinue their medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effects of Glycine on Symptoms and Memory in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males aged 18-65 with DSM-IV diagnosis of schizophrenia or schizoaffective disorder by diagnostic interview and chart review~2. Clinically stable on a stable dose of antipsychotic medication (any except clozapine or olanzapine) for at least one month, no current active suicidal ideation~3. Not treated with investigational medication in the past 30 days~4. Competent to provide informed consent~Exclusion Criteria:~1. Diagnosis of dementia, neurodegenerative disease, seizure disorder, current substance abuse or dependence disorders, including alcohol, active within the last 3 months or any Axis I DSM-IV diagnosis other than schizophrenia or schizoaffective disorder~2. Serious illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease that is not stabilized such that hospitalization for treatment of that illness is likely within the next four months~3. Patients who, in the investigator's opinion, pose a current severe homicide or suicide risk~4. History of multiple head injuries with neurological sequelae or a single severe head injury with lasting neurological sequelae~5. Uncontrolled hypertension~6. Anuretic~7. Use of clozapine or olanzapine in the past month~8. Subjects who weigh more than 275 lbs~9. Subjects who are claustrophobic~10. Subjects with a history of electrolyte imbalance~11. Subjects who have lost consciousness for 30 minutes or more~12. Subjects with lifetime history of stroke~13. Subjects with myocardial infarction within the last 6 months~14. Those having a pacemaker or a heart arrhythmia~15. Source of metal in body incompatible with MRI procedures~16. Those who have ever used a dietary glycine supplement

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Obstructive Airways Diseases in Emergency Department (OADED) Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age \>18~2. Ability and willingness to participate the study and sign informed consent form~3. Asthma / COPD patients~Exclusion Criteria:~1. Pregnant women~2. Asthma or COPD patients with FEV1 \> 60%~3. Disability or unwillingness to undergo capnography measurement~4. Cannot be assessed for FEV1~5. Oxygen supply \>5 L/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with COPD and Asthma . (Type: None): Patients with COPD and Asthma. Continuous capnography and spirometry measurements of the subjects will be taken form the subjects with at least two minutes recording before the first spirometry assessment.~All clinical diagnoses and treatments will be performed according to the department's protocols.~This is an observational study with no interventions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Restoration of Chronotropic Competence in Heart Failure Patients With Normal Ejection Fraction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are in sinus rhythm~* Patients who are on stable medical therapy~* Patients who exhibit signs and symptoms of heart failure, New York Heart Association (NYHA) Class II or III~* Patients who have experienced a hospitalization for decompensated heart failure; treatment for pulmonary congestion or volume overload; chronic treatment with a loop diuretic; or a brain natriuretic peptide (BNP) \> 125 ng/l.~* Left ventricular ejection fraction (LVEF) ≥ 50%~Exclusion Criteria:~* Patients with persistent atrial fibrillation or atrial flutter~* Patients who are in complete heart block~* Patients who have experienced a recent myocardial infarction (MI) or have unstable angina or require cardiac surgery or other procedures~* Patients who have severe heart valve disease or valve replacement~* Patients with a contraindication for a pacemaker system~* Patients who have a neuromuscular, orthopedic or other non-cardiac condition that prevents patient from exercise testing~* Patients who have infiltrative or hypertrophic cardiomyopathy~* Patients who have known severe pulmonary disease~* Patients with uncontrolled diabetes or blood pressure (systolic blood pressure (SBP) \> 160 mmHg or diastolic blood pressure (DBP) \> 95 mmHg)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RAP On then Off at 1 month visit (Type: EXPERIMENTAL): 1. Rate Adaptive Pacing (RAP) On for first cardiopulmonary exercise test (CPX) at one month.~2. Rate Adaptive Pacing (RAP) Off for second cardiopulmonary exercise test (CPX) at one month.
- RAP Off then On at 1 month visit (Type: EXPERIMENTAL): 1. Rate Adaptive Pacing (RAP) Off for first cardiopulmonary exercise test (CPX) at one month.~2. Rate Adaptive Pacing (RAP) On for second cardiopulmonary exercise test (CPX) at one month.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with cancer and confirmed pulmonary embolism (PE) or deep vein thrombosis (DVT) of the leg who have been treated for minimally 6 and maximally 12 months with therapeutic doses of anticoagulants, i.e. LMWH or VKA or a new anticoagulant in a trial~2. Written informed consent~3. Indication for long-term anticoagulant therapy (e.g. because of metastasized disease, chemotherapy)~Exclusion Criteria:~1. Legal age limitations (country specific), minimum age at least 18 years~2. Indications for anticoagulant therapy other than DVT or PE~3. Any contraindication listed in the local labeling of LMWH or VKA~4. Childbearing potential without proper contraceptive measures, pregnancy or breastfeeding~5. Life expectancy \<3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vitamin K antagonists (Type: ACTIVE_COMPARATOR): None
- Low molecular weight heparin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed HER2-negative adenocarcinoma of the breast~* Locally advanced (Stage 3B) or metastatic (Stage 4) disease~* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2~* Received up to 2 prior chemotherapy regimens (not including neoadjuvant/adjuvant therapy) for advanced or metastatic disease~* Participants with hormone-receptor positive tumors must have failed available lines of hormonal therapy unless hormone therapy was not tolerated or not clinically appropriate~* ≥ 2 weeks elapsed from the completion of previous treatment regimen and must have recovered or be at a new stable baseline from any related toxicities~* Radiographically measurable or evaluable disease~* An mGPS of 1 or 2 as defined below:~  * Criteria:~    1. modified Glasgow prognostic score (mGPS) of 1: CRP \> 10 mg/L and albumin ≥ 35 g/L~   2. mGPS of 2: C-reactive protein (CRP) \> 10 mg/L and albumin \< 35 g/L~Exclusion Criteria:~* Received prior treatment with capecitabine or fluoropyrimidine for advanced or metastatic disease~* Received more than 2 prior regimens for advanced or metastatic disease (not including hormonal therapy in the metastatic setting or neoadjuvant or adjuvant therapies)~* Unknown hormone-receptor status~* Ongoing radiation therapy or radiation therapy administered within 2 weeks of enrollment~* Concurrent anticancer therapy~* Inadequate renal, hepatic or bone marrow function~* Another current or previous malignancy within 2 years of study entry unless approved by the sponsor

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment A - Capecitabine and ruxolitinib (Type: EXPERIMENTAL): None
- Treatment B - Capecitabine and placebo (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Disposable Flexible Bronchoscope, aScope IV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult 18 years old and older~2. Capable of giving informed consent or have an acceptable surrogate capable of giving legally authorized consent on the subject's behalf.~3. Indication of a diagnostic and or therapeutic bronchoscopy as determined by the attending critical care physician~4. Being cared for in the critical care units at the U of L Hospital~Exclusion Criteria:~1) Patient is moribund and a bronchoscopy is very unlikely to reduce impending mortality or can avert death

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Disposable bronchoscope first (aScope IV), then Reusable bronchoscope (Storz 8402 2x) (Type: EXPERIMENTAL): the bronchoscope will be re-inserted and advanced to the basal segmental bronchi of the right lower lobe. The tip of the bronchoscope will be brought into wedge position in one of the basal segments for broncho-alveolar lavage (BAL). A saline flush of 20 ml will be administered. The flow of saline will be observed at the distal tip of the bronchoscope. After 10 seconds of maintaining a wedge position, gentle suction will be applied to collect the lavage specimen in the collection trap. This step will be repeated 4 more times (total of 80ml) to obtain an adequate specimen.
- Reusable bronchoscope first (Storz 8402 2x), then Disposable bronchoscope (aScope IV) (Type: ACTIVE_COMPARATOR): the bronchoscope will be re-inserted and advanced to the basal segmental bronchi of the right lower lobe. The tip of the bronchoscope will be brought into wedge position in one of the basal segments for broncho-alveolar lavage (BAL). A saline flush of 20 ml will be administered. The flow of saline will be observed at the distal tip of the bronchoscope. After 10 seconds of maintaining a wedge position, gentle suction will be applied to collect the lavage specimen in the collection trap. This step will be repeated 4 more times (total of 80ml) to obtain an adequate specimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
The subjects in this study will be subjects with central-involved DME (CI-DME). Both treatment-naïve and previously treated subjects will be included.~Inclusion Criteria:~* Written informed consent obtained from the subject prior to screening procedures~* Male or female aged 18 years or older at the time of signing the informed consent~* Type 1 or type 2 diabetes~* BCVA ETDRS letter score ≥ 39 in the study eye~* CI-DME with CST of ≥ 300µm in men (or equivalent in women), measured from RPE to ILM inclusively, on SD-OCT, in the study eye~* BCVA ETDRS letter score ≥ 34 in the fellow eye~Exclusion Criteria:~* Macular edema due to causes other than DME in the study eye~* Concurrent disease in the study eye, other than DME, that could require medical or surgical intervention during the study period or could confound interpretation of the results~* Any condition in the study eye that could confound the ability to detect the efficacy of the investigational medicinal product~* Previous confounding medications / interventions, or their planned administration during the study~* Presence of iris neovascularisation in the study eye~* Uncontrolled glaucoma in the study eye~* Previously received THR-687 or any other experimental therapy for DME, in either eye~* Any active or suspected ocular or periocular infection, or active intraocular inflammation, in either eye~* Untreated Diabetes~* Glycated haemoglobin A (HbA1c) \> 12%~* Uncontrolled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part A, THR-687 1.2 mg (Type: EXPERIMENTAL): None
- Part A, THR-687 2.0mg (Type: EXPERIMENTAL): None
- Part B, treatment naïve subjects, THR-687 selected dose level (Type: EXPERIMENTAL): Due to the discontinuation of the study after Part A, the dose level for Part B has not been selected
- Part B, treatment naïve subjects, aflibercept 2.0mg (Type: ACTIVE_COMPARATOR): None
- Part B, previously treated subjects, THR-687 selected dose level (Type: EXPERIMENTAL): Due to the discontinuation of the study after Part A, the dose level for Part B has not been selected
- Part B, previously treated subjects, aflibercept 2.0mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of myelodysplastic syndrome (MDS), according to World Heath Organization or the French-American-British Cooperative Group pathologic classification, with an International Prognostic Scoring System score 0, 0.5, or 1.0, indicating Low- or INT-1-risk disease.~* Documented RBC transfusion of at least 2 units of RBC for the treatment of the anemia of MDS in the 8 weeks preceding the start of the Screening Period.~* Adequate iron stores, demonstrated by either the presence of stainable iron in the bone marrow or a serum ferritin of \> 100 ng/mL.~* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2.~* Symptomatic anemia (defined by a score \> 0 on the Non-Chemotherapy Anemia Symptom Scale \[NCA-SS\]).~Exclusion Criteria:~* Had treatment with drugs or other agents targeting IL-6 or its receptor within 4 weeks of randomization.~* Any condition that, in the opinion of the investigator, would make participation not in the best interest (eg, compromise the well-being) of the patient or that could prevent, limit, or confound the protocol-specified assessments.~* Patients with Chronic Myelomonocytic Leukemia (CMML).~* Causes other than MDS contributing to anemia, such as Vitamin B12 or folate deficiency, bleeding, hemolysis, hemoglobinopathy, or chronic renal failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Siltuximab (Type: EXPERIMENTAL): 15 mg/kg of siltuximab administered as a 1-hour infusion every 4 weeks + best supportive care (BSC)
- Placebo (Type: EXPERIMENTAL): Placebo administered as a 1-hour infusion every 4 weeks + BSC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy